ME Therapeutics investor Dhanji acquires shares

Mr. Rahim Dhanji, a shareholder, reports EARLY WARNING REPORT This news release has been disseminated as required by National Instrument 62-103 (the Early Warning System and Related Take-Over Bid and Insider Reporting Issues) in connection with the filing of the early warning report regarding the acquisition of securities of ME Therapeutics Holdings Inc., by Rahim Dhanji either directly or indirectly through 1307622 B.C. Ltd., a company controlled by Mr. Dhanji. On Jan. 26, 2025, the acquiror exercised an aggregate of 1.6 million common share purchase warrants of the company at an exercise price of 25 cents per common share purchase warrant to acquire an aggregate of 1.6 million common shares of the company for the aggregate purchase price of $400,000. Prior to the warrant exercise, the acquiror held an aggregate of 2,248,115 common shares, directly and indirectly, representing 8.58 per cent of the outstanding common shares. Subsequent to the warrant exercise, the acquiror's holdings were increased to 3,848,115 common shares, representing 13.01 per cent of the total outstanding common shares. Subsequent to the warrant exercise, the acquiror acquired an aggregate of 3,875 common shares through the facilities of the Canadian Securities Exchange at an average market price of $9.06 per common share. Following the market purchases, the acquiror's direct and indirect holdings increased to 3,851,990 common shares, representing 13.02 per cent of the outstanding common shares as of today's date. The common shares acquired by the acquiror were acquired for investment purposes. In the future, the acquiror may, directly or indirectly, acquire additional common shares or dispose of such common shares subject to a number of factors, including, without limitation, general market and economic conditions, and other investment and business opportunities available. A copy of the early warning report to be filed by the acquiror will be available on SEDAR+ under the company's profile. This early warning news release is issued under the early warning provisions of Canadian securities legislation, including National Instrument 62-104 (Take-Over Bids and Issuer Bids) and National Instrument 62-103 (the Early Warning System and Related Take-Over Bid and Insider Reporting Issues).